When there is a risk of shortage of some medicines in Russia, measures are taken to ensure their rapid availability on the market. Russian Health Minister Mikhail Murashko stated this in an interview RIA News In SPIEF.
“We make decisions about rapid access to the medicines the country needs in case some risks arise. This mainly applies to generics and biosimilars,” Murashko noted.
He emphasized that innovative drugs that can save patients’ lives can also be brought to market with a simplified procedure. At the same time, standards for the conduct of clinical trials are not reduced and a high-quality evidence base is collected.
After a drug is authorized, monitoring continues to ensure that high quality and effectiveness are maintained. Therefore, the process of rapid access to medicines does not affect the quality and effectiveness of medicines.
Previously, it was reported through compulsory health insurance excluded two anti-cancer drugs that have no analogues. Since 2024, the purchase of drugs “Abraxan” and “Picray” at the expense of the Compulsory Health Insurance Fund has been stopped.
Russian scientists before developed import substitution veterinary medicine.